证券代码：002030 证券简称：达安基因 公告编号：2026-006 医疗器械名称：人类免疫缺陷病毒抗原抗体检测试剂盒（化学发光免疫分析 法），注册证编号：国械注准 20263400639。有效期自批准之日起至 2031 年 3 月 26 日。预期用途：本试剂盒主要用于体外定性检测人血清或血浆中的人类免 疫缺陷病毒（HIV）-1 型/2 型抗体和 HIV-1 p24 抗原。 目前，公司控股子公司广州市达瑞生物技术股份有限公司已获得"人类免疫 缺陷病毒抗原抗体检测试剂盒（化学发光免疫分析法）"的医疗器械注册证，上 述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投资者注意投资风 险。 特此公告。 广州达安基因股份有限公司 董 事 会 2026 年 3 月 31 日 广州达安基因股份有限公司 关于下属子公司取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，本公司下属控股子公司广州市达瑞生物技术股份有限公司取得国家药 品监督管理局颁发的医疗器械注册证一个，具体为： ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司（以下简称"公司"）于 2026 年 3 月 20 日以 邮件的形式发出第九届董事会 2026 年第二次临时会议通知，并于 2026 年 3 月 25 日（星期三）上午 10：00 以通讯表决的方式召开。会议应出席董事 11 名， 实际出席董事 11 名，会议由董事长韦典含女士主持。本次会议的召集、召开符 合《公司法》《公司章程》以及有关法律、法规的规定。本次会议以投票表决 的方式通过并形成书面决议如下： 一、会议以 7 票赞成，0 票反对，0 票弃权的表决结果审议通过了公司《关 于发放 2025 年度高级管理人员三个月职级工资的议案》。关联董事陈宏威先生、 黄志征先生、张为结先生、梁志坤先生回避表决。 结合公司 2025 年度经营情况和全体经营班子成员（含高级管理人员）的工 作表现，公司全体经营班子成员（含高级管理人员）2025 年度增加发放三个月 职级工资；对于参与子公司专项激励或劳动合同中另有约定的则从其规定，不 重复领取三个月职级工资。 本议案已经第九届董事会薪酬与考核委员会 20 ...

Group 1 - The core point of the article is that Da An Gene (002030) reported its total number of shareholders as approximately 170,000 as of January 30, 2026 [1] Group 2 - The company only provides the number of shareholders at the end of each month [1]

Core Viewpoint - The company, Da An Gene (002030), indicated that its 2025 annual performance forecast is based on preliminary calculations by the finance department, with performance fluctuations influenced by multiple factors including centralized procurement and healthcare cost control policies, as well as changes in the external macroeconomic environment [1] Financial Performance - The company is taking measures to address operational challenges by focusing on sustainable development and maximizing shareholder interests, which includes implementing cost-saving initiatives and enhancing operational efficiency [1] - The company has recognized impairment indicators for certain assets and has made provisions for asset impairment to solidify asset quality [1] - Final financial data will be disclosed in the officially audited 2025 annual report [1]

Group 1 - The core point of the article is that DaAn Gene (002030) has approximately 170,000 total shareholders as of January 30, 2026 [1]

Group 1 - The company, DaAn Gene, stated that it strictly adheres to laws, regulations, and accounting standards in its information disclosure and financial management, ensuring compliance in its operations without any financial fraud [2] - The company's performance is influenced by various factors including industry cyclicality, market competition, and industry policies [2] - Investors are advised to pay attention to the company's upcoming annual report for 2025, which will be disclosed on April 3, 2026 [2]

Core Viewpoint - Da An Gene (002030) expects a net profit loss attributable to shareholders of approximately 607 million to 865 million yuan for the fiscal year 2025, showing improvement compared to a loss of 925 million yuan in the same period last year [1] Group 1: Financial Performance - The main reasons for the performance change include a decrease in operating revenue due to market demand and adjustments in the value-added tax rate for self-produced reagent products [1] - The company has implemented various cost-saving measures to enhance operational efficiency, but the fixed costs such as operational and labor costs remain high, making it difficult for the revenue decline to match the cost reduction in the short term, negatively impacting the overall gross profit [1] Group 2: Investment and Earnings - During the reporting period, the performance of the company's joint ventures improved compared to the previous year, leading to an increase in investment income recognized from joint ventures [1] - The net profit attributable to shareholders of the listed company increased compared to the same period last year [1]

Core Viewpoint - The company DaAn Gene announced an expected net profit attributable to shareholders for 2025 to be between -865 million yuan and -607 million yuan, compared to -925 million yuan in the same period last year, indicating a slight improvement in losses [1][4]. Financial Summary - The projected net profit attributable to shareholders for 2025 is between -865 million yuan and -607 million yuan, while the previous year's figure was -925 million yuan [2][5]. - The net profit after deducting non-recurring gains and losses is expected to be between -938 million yuan and -658 million yuan, compared to -823 million yuan in the same period last year [2][5]. - Basic earnings per share are projected to be between -0.62 yuan and -0.43 yuan, compared to -0.66 yuan in the previous year [2][5]. - For the first three quarters of 2025, the company reported revenue of 504 million yuan and a net profit attributable to shareholders of -142 million yuan, with a significant decline expected in the fourth quarter [2][5]. Reasons for Performance Changes - The decrease in operating revenue is attributed to market demand, the implementation of centralized procurement policies, and an increase in the VAT rate on self-produced reagent products to 13%. Despite efforts to enhance operational efficiency, fixed costs have led to a negative impact on gross profit, resulting in operational losses for the year [3][6]. - The performance of joint ventures improved compared to the previous year, leading to an increase in investment income recognized by the company, which positively affected the net profit attributable to shareholders [3][6]. - The company has strengthened the collection of historical accounts receivable, resulting in a decrease in the provision for credit impairment losses compared to the previous year. However, the company also conducted a comprehensive review of various assets and recognized impairment losses on assets showing signs of impairment, which increased compared to the previous year [3][6]. - The fair value of other non-current financial assets increased, contributing to a rise in net profit attributable to shareholders, with this non-recurring gain before tax increasing by approximately 180 million yuan compared to the previous year [3][6].

Core Viewpoint - The company DaAn Gene has released its annual performance forecast, expecting a significant net loss for 2025, primarily due to decreased revenue from market demand and policy impacts, despite some improvements in investment income from joint ventures [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between -607 million to -865 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -938 million to -658 million yuan [1] Group 2: Revenue and Cost Factors - The decrease in revenue is attributed to market demand, the implementation of centralized procurement, and an increase in the value-added tax rate on self-produced reagent products to 13% [1] - Despite efforts to enhance operational efficiency and reduce costs, the fixed costs such as operational and labor costs remain high, leading to a negative impact on overall gross profit [1] Group 3: Investment and Asset Management - The performance of joint ventures has improved compared to the previous year, resulting in an increase in investment income recognized by the company [1] - The company has strengthened its collection of historical accounts receivable, leading to a reduction in the provision for credit impairment losses compared to the previous year [1] - A comprehensive asset review was conducted, and impairment tests were performed on assets showing signs of impairment, resulting in an increase in the provision for asset impairment losses compared to the previous year [1] Group 4: Non-Recurring Gains - The fair value of other non-current financial assets has increased, contributing to a rise in net profit attributable to shareholders compared to the previous year, with non-recurring gains before tax increasing by approximately 180 million yuan [1]

Core Viewpoint - The company DaAn Gene expects a net profit attributable to shareholders of between -865 million to -607 million yuan for 2025, an improvement from -925 million yuan in the same period last year [1] Financial Performance - The expected net profit after deducting non-recurring items is projected to be between -938 million to -658 million yuan, compared to -823 million yuan in the previous year [1] - The performance fluctuation is primarily due to decreased revenue from market demand, centralized procurement policies, and tax rate adjustments, leading to operational losses [1] Investment and Asset Management - Improved performance from joint ventures has resulted in increased investment income [1] - The company has strengthened the collection of accounts receivable, leading to a reduction in related credit impairment losses, although asset impairment losses have increased [1] - The fair value of other non-current financial assets has risen, with non-recurring gains before tax increasing by approximately 180 million yuan [1]